Anticoagulation in Atherosclerotic Disease

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Thrombosis Research

Background:

• Atherothrombotic events are a major concern in arteriosclerotic diseases, leading to heart attack, stroke, and limb ischemia.
• Current prevention strategies for stable patients rely on antiplatelet agents like aspirin and clopidogrel, but recurrent ischemic events persist.
• Excessive thrombin generation contributes to ongoing cardiovascular risk despite antiplatelet therapy.

Purpose of the Study:

• To evaluate the efficacy and safety of low-dose anticoagulation with a factor Xa inhibitor in patients with stable coronary heart disease or peripheral arterial disease.
• To assess the impact of combining rivaroxaban with aspirin on cardiovascular outcomes and mortality.

Main Methods:

• The COMPASS study investigated the addition of low-dose rivaroxaban (2.5 mg twice daily) to long-term aspirin therapy.
• Participants had stable coronary heart disease or peripheral arterial disease.
• Outcomes were compared between the rivaroxaban-aspirin group and aspirin monotherapy.

Main Results:

• The combination of rivaroxaban and aspirin significantly reduced cardiovascular death, myocardial infarction, and stroke.
• All-cause mortality was reduced by a relative 18% in the treatment group.
• An increase in gastrointestinal bleeding was observed, but fatal or intracranial hemorrhages did not increase.

Conclusions:

• Low-dose anticoagulation with rivaroxaban in addition to aspirin represents a new therapeutic strategy for high-risk patients with atherosclerotic disease.
• This regimen offers significant benefits in preventing major adverse cardiovascular events and reducing overall mortality.
• Further research is needed to manage bleeding risks, potentially with proton pump inhibitors.